ARCHIVES

News Analysis by Keith Baggerly: Duke Trials Went On Despite FDA Statements

This article is from The Cancer Letter archive.

Vol. 38 No. 04 | January 27, 2012

Download PDF Visit The Full Archive

Related Articles

NCCS Urges FDA To Finalize Regulations On Expanded Access.

December 19, 2008

NCI-Approved Protocols Listed

December 26, 2003

Two Second-Line CML Drugs Work Front-Line, Studies Find

January 29, 2010

Report Urges Changes To Cut Activation Times For NCI Phase III Trials.

April 9, 2010

In Brief : Patricia LoRusso Named Associate Director Of Innovative Medicine at Yale Cancer Center

June 20, 2014

Study Would Try to Validate EGFR FISH as Predictive Marker for Benefit from Tarceva.

July 13, 2007